These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 1856950)

  • 21. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Sarosdy MF; Lamm DL
    J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.
    Pommier JD; Ben Lasfar N; Van Grunderbeeck N; Burdet C; Laouénan C; Rioux C; Pierre-Audigier C; Meybeck A; Choudat L; Benchikh A; Nguyen S; Bouvet E; Yeni P; Yazdanpanah Y; Joly V
    Infect Dis (Lond); 2015; 47(10):725-31. PubMed ID: 26077036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
    Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
    J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
    Lamm DL; van der Meijden PM; Morales A; Brosman SA; Catalona WJ; Herr HW; Soloway MS; Steg A; Debruyne FM
    J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disseminated Bacillus Calmette-Guérin (BCG) infection and acute exacerbation of interstitial pneumonitis: an autopsy case report and literature review.
    Shimizu G; Amano R; Nakamura I; Wada A; Kitagawa M; Toru S
    BMC Infect Dis; 2020 Sep; 20(1):708. PubMed ID: 32993546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
    Böhle A; Rüsch-Gerdes S; Ulmer AJ; Braasch H; Jocham D
    J Urol; 1996 Jun; 155(6):1892-6. PubMed ID: 8618281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
    Brosman SA; Lamm DL
    J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.
    Deresiewicz RL; Stone RM; Aster JC
    J Urol; 1990 Dec; 144(6):1331-3; discussion 1333-4. PubMed ID: 2231918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
    Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
    Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
    Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
    J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
    Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Onur O; Celiker R
    Clin Rheumatol; 1999; 18(1):74-6. PubMed ID: 10088958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.